Get the Stockscreener App
13.46
4.10%
+0.53
Elanco Animal Health Inc stock is currently priced at $13.46, with a 24-hour trading volume of 4.75M.
It has seen a +4.10% increased in the last 24 hours and a -14.92% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $12.95 pivot point. If it approaches the $13.64 resistance level, significant changes may occur.
Previous Close:
$12.93
Open:
$13
24h Volume:
4.75M
Market Cap:
$6.65B
Revenue:
$4.42B
Net Income/Loss:
$-1.23B
P/E Ratio:
-67.30
EPS:
-0.2
Net Cash Flow:
$117.00M
1W Performance:
-1.32%
1M Performance:
-14.92%
6M Performance:
+47.91%
1Y Performance:
+34.87%
1D Range:
$12.97
$13.73
52W Range:
$7.88
$16.88
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 Innovation Way, Greenfield
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Breaking Down Elanco Animal Health: 6 Analysts Share Their Views
Benzinga
Elanco Animal Health (ELAN) Q4 2023 Earnings Call Transcript
The Motley Fool
Here's What Key Metrics Tell Us About Elanco Animal Health Incorporated (ELAN) Q4 Earnings
Zacks Investment Research
US Stocks Could Pause For Breather After Record Rally: Analyst Says 'No Doubt' That 2024 Shaping Up To 'Best Year Since 1999'
Benzinga
Analysts Estimate U.S. Physical Therapy (USPH) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Elanco Animal Health Incorporated (ELAN) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Zacks Investment Research
Elanco Animal Health Inc Stock (ELAN) Financials Data
Elanco Animal Health Inc (ELAN) Revenue 2024
ELAN reported a revenue (TTM) of $4.42 billion for the quarter ending December 31, 2023, a +0.11% rise year-over-year.
Elanco Animal Health Inc (ELAN) Net Income 2024
ELAN net income (TTM) was -$1.23 billion for the quarter ending December 31, 2023, a -1,478% decrease year-over-year.
Elanco Animal Health Inc (ELAN) Cash Flow 2024
ELAN recorded a free cash flow (TTM) of $117.00 million for the quarter ending December 31, 2023, a -56.34% decrease year-over-year.
Elanco Animal Health Inc (ELAN) Earnings per Share 2024
ELAN earnings per share (TTM) was -$2.50 for the quarter ending December 31, 2023, a -1,462% decline year-over-year.
Elanco Animal Health Inc Stock (ELAN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DOYLE WILLIAM F | Director |
Mar 08 '24 |
Buy |
16.30 |
15,000 |
244,500 |
61,330 |
| Harrington Michael J | Director |
Mar 08 '24 |
Buy |
16.29 |
3,100 |
50,494 |
77,594 |
| HOOVER R DAVID | Director |
Mar 06 '24 |
Buy |
16.14 |
20,000 |
322,808 |
185,000 |
About Elanco Animal Health Inc
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production. It sells its products to third-party distributors; veterinarians; and food animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal Health Incorporated is a subsidiary of Eli Lilly and Company.
0.71%
0.98%
Cap:
|
Volume (24h):